$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.THE MODERN
LEAP
Health / Public Health

China Adds 107 Drugs to Insurance List, First CAR-T Included

China's National Healthcare Security Administration unveiled its 2026 insurance drug list in Suzhou on Saturday, November 14, adding 107 medicines — a record 51 of them Class 1 innovative drugs — and bringing the total to 3,331. For the first time, a CAR-T cancer therapy, JW Therapeutics' relmacabtagene autoleucel, joins the basic list. The new list takes effect on January 1, 2027.

Inside a pharmacy in Nanning, China (archive). Photo: Félix An / CC BY 4.0, via Wikimedia Commons.
Summary

A therapy that cost more than a million yuan a dose just entered the system that pays ordinary hospital bills. The negotiated price isn't public, but the door it walked through is the story.

Tap a passage. React to the part that matters.

China added 107 drugs to the national catalog of medicines its basic medical insurance covers, the National Healthcare Security Administration announced in Suzhou, Jiangsu province, on Saturday, November 14. Fifty-one of the additions are Class 1 innovative drugs — medicines not yet marketed in China or overseas — a record number for a single update. The revised list removes 34 drugs and brings the total to 3,331.

The headline addition is a first. JW Therapeutics' relmacabtagene autoleucel injection, a CAR-T cell therapy for adults with certain lymphomas that have returned or stopped responding to treatment, becomes the first CAR-T product in the basic insurance catalog — and, the company said, the only one added this year. CAR-T therapies are built from a patient's own immune cells and have carried prices above 1 million yuan per dose in China.

What patients will actually pay isn't in the announcement. Prices for drugs entering the list are set through negotiation and generally aren't published, so estimates circulating in industry coverage — some putting the patient's share after reimbursement below 100,000 yuan — remain estimates until hospitals bill against the new list. The list itself takes effect on January 1, 2027.

The additions reach beyond cancer. The administration said the new entries cover tumors, rare diseases, chronic illnesses and mental disorders, among the areas with the most urgent clinical need. The full catalog now holds 1,935 Western medicines and 1,396 Chinese patent medicines. This year, 424 drugs from outside the list applied to join it.

A second list moved in parallel. The commercial health insurance innovative drug catalog, introduced in December 2025, added 12 medicines and now holds 28. NHSA head Zhang Ke said at the Suzhou conference that the administration built a mechanism this year to link the two lists, opening more pathways for innovative medicines to reach patients — basic insurance for the broad catalog, commercial coverage layered on top.

Individual products show the range of what got in. Innovent Biologics' mazdutide, a domestically developed dual-target drug for weight loss and blood-sugar control, joined the list, as did Baili Tianheng's iza-bren in its first year on the market. On the commercial list, the 12 additions include the world's first CAR-T therapy for solid tumors and China's first gene therapy drug for hemophilia — products priced for the commercial tier while the basic list takes the broader catalog.

The record count of innovative drugs is the policy signal. Class 1 drugs are the industry's newest and most expensive products, and putting 51 of them into the basic scheme in one year shifts the negotiation balance: manufacturers trade a lower, undisclosed price for access to the largest insured patient pool in the world. Whether that trade holds depends on the prices nobody outside the room has seen.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.